CLOZAID – Randomized Clinical Trial – Clozapine for treatment-resistant psychosis in people with intellectual disability
CLOZAID
EUDRACT 2020-000091-37
NCT04529226
A randomized, multicenter clinical trial to assess the safety and tolerability of clozapine vs treatment as usual for treatment-resistant psychosis in adolescents and young adults with intellectual disability
Sponsor: Carlos III Health Institute. ICI19_0026
Primary objective:
To evaluate the efficacy of clozapine vs usual clinical practice treatment in subjects with intellectual disability associated with a psychotic disorder on measures of scoring change from baseline in the ICG-SCH (The Clinical Global Impression–Schizophrenia scale) to the end of the study.
Recruiting Centers
With the kind support of
